Related Experiment Video
Updated: Jan 29, 2026

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells
Zhi-Chuan Zhu1, Ji-Wei Liu2, Can Yang1,3
1State Key Laboratory of Neuroscience, Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with potential anticancer effect, but innate and adaptive TRAIL resistance in majority of cancers limit its clinical application. Karyopherin β1 (KPNB1) inhibition in cancer cells has been reported to abrogate the nuclear import of TRAIL receptor DR5 and facilitate its localization on the cell surface ready for TRAIL stimulation. However, our study reveals a more complicated mechanism. Genetic or pharmacological inhibition of KPNB1 potentiated TRAIL-induced apoptosis selectively in glioblastoma cells mainly by unfolded protein response (UPR). First, it augmented ATF4-mediated DR5 expression and promoted the assembly of death-inducing signaling complex (DISC). Second, it freed Bax and Bak from Mcl-1. Third, it downregulated FLIPL and FLIPS, inhibitors of caspase-8 cleavage, partly through upregulating ATF4-induced 4E-BP1 expression and disrupting the cap-dependent translation initiation. Meanwhile, KPNB1 inhibition-induced undesirable autophagy and accelerated cleaved caspase-8 clearance. Inhibition of autophagic flux maintained cleaved caspase-8 and aggravated apoptosis induced by KPNB1 inhibitor plus TRAIL, which were abolished by caspase-8 inhibitor. These results unveil new molecular mechanism for optimizing TRAIL-directed therapeutic efficacy against cancer.
Insights
Inhibiting Karyopherin β1 (KPNB1) enhances cancer cell death by boosting TRAIL signaling through the unfolded protein response (UPR). This strategy overcomes TRAIL resistance, offering a new approach for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows anticancer potential but faces resistance in many cancers.
- Karyopherin β1 (KPNB1) inhibition was previously thought to enhance TRAIL efficacy by increasing cell surface DR5.
- The precise mechanisms by which KPNB1 inhibition impacts TRAIL sensitivity remain incompletely understood.
Purpose of the Study:
- To elucidate the detailed molecular mechanisms by which KPNB1 inhibition sensitizes glioblastoma cells to TRAIL-induced apoptosis.
- To investigate the role of the unfolded protein response (UPR) in KPNB1 inhibition-mediated sensitization to TRAIL.
- To identify novel therapeutic targets for optimizing TRAIL-based cancer treatments.
Main Methods:
- Utilized genetic and pharmacological inhibition of KPNB1 in glioblastoma cell lines.
- Investigated the role of the unfolded protein response (UPR) pathway, including ATF4 and 4E-BP1.
- Assessed the expression and function of apoptosis-related proteins such as DR5, Bax, Bak, Mcl-1, FLIPs, and caspase-8.
- Analyzed the impact of autophagy inhibition on apoptosis induction and caspase-8 stability.
- Employed caspase-8 inhibitors to confirm the role of caspase-8 in observed apoptosis.
Main Results:
- KPNB1 inhibition potentiated TRAIL-induced apoptosis selectively in glioblastoma cells via the UPR.
- Enhanced DR5 expression and death-inducing signaling complex (DISC) assembly were observed.
- KPNB1 inhibition led to the release of Bax and Bak from Mcl-1 and downregulated FLIP variants.
- Autophagy was induced by KPNB1 inhibition, accelerating cleaved caspase-8 clearance; inhibiting autophagy flux enhanced apoptosis.
- The pro-apoptotic effect was dependent on caspase-8 activity.
Conclusions:
- KPNB1 inhibition sensitizes glioblastoma to TRAIL through a complex UPR-mediated mechanism involving DR5 upregulation, altered Bcl-2 family protein balance, and modulation of FLIPs.
- Autophagy plays a dual role, and its inhibition can enhance TRAIL efficacy when combined with KPNB1 inhibition.
- These findings reveal a novel molecular framework for improving TRAIL-directed cancer therapy.
More Related Videos
Related Concept Videos
Negative Regulator Molecules
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated mRNA Transport
Positive Regulator Molecules
Epigenetic Regulation

